Mission
To promote the highest quality patient-centered neurologic care and enhance member career satisfaction

Vision
To be indispensable to our members
Overview

What is Advocacy?
- Anticipate changes in healthcare delivery systems
- Influence the legislative and regulatory process, decisions, and structures
- Engage our members & patient groups to become partners in the process

Perfect Issue
- Important to Neurology
- Available Resources
- Stakeholder Alignment
- Legislative Opportunity

#AANADVOCACY

8/21/2019
Maximize Effort

- Health Care Policy
- Important to Medicine
- Important to Neurology
- AAN Can Influence Outcomes

Influence Has Many Forms

- Bills
- Sign-on Letters
- Media
- Hearings
- Speeches
- Inquiries

How Can AAN Influence Policy?

- Position Statements
- AAN Comment Letters
- Sign-on Letters
- Coalitions
- Partnerships
- Grassroots
- BrainPAC
- Relationships
- Public Relations/Social Media
AAN Washington, DC Presence

- 2005: DC office opened with one lobbyist
- 2019: DC office now has 6 staff
  - 2 Lobbyists & 1 PAC Manager
  - 2 Regulatory Staff
  - 1 Health Policy Expert

AAN Health Policy Structure

Advocacy Committee

- Defines strategic direction to achieve the AAN's health policy goals at all levels of government
  - State and federal
  - Legislative and regulatory
  - Streamlined approach
  - Seeks to maximize AAN's impact
2019 Priority Issues

<table>
<thead>
<tr>
<th>Active Issues</th>
<th>Monitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Workforce, telemedicine, scope of practice, EHR Reform, opioids and pain</td>
<td>Gun Safety, Health Care Principles, TBI/Concussion, Neuroimaging,</td>
</tr>
<tr>
<td>research, neuro research funding, VA Centers of Excellence, Medical Marijuana</td>
<td>Liability Reform, Neurologic Disease Surveillance, immigration, Narrow networks</td>
</tr>
<tr>
<td>Research, MACRA fixes</td>
<td></td>
</tr>
</tbody>
</table>

Reducing Regulatory Burdens

• In 2018 Congress passed the Standardizing ePA for Safe Prescribing Act
  • Standardizes electronic prior authorization in Medicare Part D and Medicare Advantage
  • Priority issue at 2018 Neurology on the Hill
  • Regulations to implement this are happening now
• Step Therapy
  • Regulatory comments on Medicare Advantage
  • Currently advocating for Safe Step Act passage in Congress which establishes common-sense exceptions to step therapy in group health plans

Prior Authorization

• Seniors' Timely Access to Care Act of 2019
  • Increase transparency and streamline prior authorization for Part B items and services in Medicare Advantage
• Kentucky Senate Bill 54 – takes effect 2020
  • Requires responses to PA requests within 24 hours for urgent services otherwise within 5 days.
  • Prescriptions for chronic-condition maintenance drugs will be valid for one year, and any change in dosage during this period will be covered.
  • PA procedures to be posted online along with list of services requiring PA.
  • PA reviewers will be licensed physicians and, when possible, of the same specialty as the requesting physician.
  • Physicians will be able to electronically request & transmit PAs.
Cognitive Reimbursement

- Shift in the past 5 years where CMS actively acknowledges AAN feedback and expertise
- Successfully fought against consolidation of E/M codes with alignment of legislative and regulatory strategies

Congratulations to the AAN!

- Won American Association of Medical Society Executives Profiles of Excellence award for collaboration and advocacy efforts related to our wins in the final 2019 Medicare Physician Fee Schedule

Drug Pricing Current Landscape

- Trump drug pricing setbacks put pressure on Congress
- White House backs importing drugs from abroad
- Congress seizes flurry of drug pricing legislation

2020 election creates ‘perfect storm’ for drug price reform by year-end
AAN Efforts to Date

- Part of the drug pricing conversation
- Reviewing and commenting on dozens of drug pricing bills including provisions on transparency, drug rebates, Medicare negotiation, and access
- Commented on many major proposals from administration
  - Direct to consumer advertising (courts struck down)
  - Step therapy and prior authorization for protected classes in Medicare Part D (scaled back proposal)
  - Drug rebate reform (withdrew proposal)
  - International pricing index for Medicare Part B drugs

Neurodisease Surveillance

- In 2016, as part of the 21st Century Cures Act, Congress authorized CDC to initiate development of a National Neurological Conditions Surveillance System
- FY2019 appropriations of $5 million
- Beginning implementation with MS and Parkinson’s
- Currently working to oppose efforts to include schizophrenia in initial system

Get Involved!
Capitol Hill Report

- Bi-weekly update on legislative action and advocacy for neurology
- Emailed to all US AAN members

Neurology on the Hill

- Neurology on the Hill (February)
- Neurology Off the Hill (August)
- Legislative Summit (September)

Increasing AAN Member’s Impact

- 230 Members
- 75 Members
- 40 Members

Increase # of Members accepted
Increase impact of AAN advocacy
Palatucci Advocacy Leadership

AAN Action Center
Grassroots features include: Emailing/tweeting/calling Congress, comment on regulation, share a link, collect stories, log interactions, bill tracking

BrainPAC: An Advocacy Tool
• Active since 2007, only political action committee dedicated solely to neurology
• Top 10 specialty PAC for the 2018 election cycle!
Help us remain in the top-ten!

• Make your 2019 donation to BrainPAC now!
• Text keyword **Neurology** to 41444 to donate to BrainPAC

Open to US Citizens or Permanent Residents

Contributions to BrainPAC are not deductible for federal income tax purposes. Contributions to BrainPAC are entirely voluntary, and you have the right to refuse to contribute without reprisal. Federal election law requires that AAN must make reasonable efforts to disclose the name, mailing address, occupation, and name of the employer of any individual whose contributions exceed $200 in any calendar year. Contributions to BrainPAC are not deductible for federal income tax purposes. Questions?